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. David Paltiel, PHD,† Rachel Lampert, MD, FACC*
ew Haven, Connecticut
OBJECTIVES The purpose of this study was to determine the least expensive strategy for device selection
in patients receiving implantable cardioverter-defibrillators (ICDs).
BACKGROUND Device cost for a single-chamber ICD is less than an atrioventricular (dual-chamber) ICD
(AV-ICD); however, some patients without clinical need for AV-ICD at implantation might
require a later upgrade, potentially offsetting the initial cost advantage of the single-chamber
device.
METHODS Decision analysis was used to estimate expected resource utilization costs of three alternative
implantation strategies: 1) single-chamber device in all, with later upgrade to AV-ICD if
needed; 2) initial implantation of an AV-ICD in all; and 3) targeted device selection on the
basis of results of electrophysiologic testing (presence or absence of induced bradyarrhythmias
or atrial arrhythmias). Clinical base estimates were obtained from retrospective review of all
patients receiving ICDs between June 1997 and July 2001 at a single university hospital.
Economic inputs were collected from national and single-center sources.
RESULTS In patients without other indications for electrophysiologic study (EPS), the expected
per-person cost was least with the strategy of universal initial AV-ICD implantation
($36,232) compared with initial single-chamber ICD/upgrade as needed ($39,230) or
EPS-guided selection ($41,130). Sensitivity analyses demonstrated that universal AV-ICD
implantation remained least expensive with upgrade rates as low as 10%. At a 5% upgrade
rate, AV-ICD remained cheapest if the device cost-differential narrowed to $1,568. For
patients undergoing EPS for risk assessment, EP-guided selection was least expensive.
CONCLUSIONS The strategy of universal AV-ICD implantation, which provides the benefits of dual-chamber
capability while obviating any potential need for future upgrade, is the least costly strategy for
most patient populations receiving ICDs. (J Am Coll Cardiol 2005;46:850–7) © 2005 by
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.061the American College of Cardiology Foundation
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ihe implantable cardioverter-defibrillator (ICD) is the
tandard of care for patients at risk for sudden cardiac death
1–4). The atrioventricular (dual-chamber) ICD (AV-
CD), approved by the Food and Drug Administration
FDA) in 1997, is indicated for patients who are at risk for
entricular tachyarrhythmias and also in need of pacing for
radycardia (5,6). Of ICD recipients, 15% to 20% require
ntibradycardia pacing, owing to intrinsic sinus node dys-
unction or conduction system disease, or use of medications
ith negative chronotropic properties (7,8). Furthermore,
atients with atrial tachyarrhythmias might benefit from the
rrhythmia detection capability afforded by the atrial lead in
he AV-ICD, which might help prevent delivery of inap-
ropriate shocks for supraventricular arrhythmias (5,9,10).
urrently, approximately 40% to 51% of ICDs implanted in
he U.S. are dual-chamber devices (industry data,
edtronic Inc., Minneapolis, Minnesota, and Guidant
orp., St. Paul, Minnesota).
Although many patients demonstrate the need for dual-
hamber capabilities at the time of initial ICD implantation,
From the Schools of *Medicine and †Epidemiology and Public Health, Yale
niversity, New Haven, Connecticut.d
Manuscript received June 25, 2004; revised manuscript received April 29, 2005,
ccepted May 17, 2005.thers develop sinus node dysfunction, AV nodal conduc-
ion disease, or atrial arrhythmias later, thereby necessitating
pgrade to a dual-chamber device. Upgrades entail repeated
urgical procedures, with rare, although serious complica-
ions such as infection, which may be more common with
e-operation than with initial implants (11,12). In addition,
he cost of a new device, along with the cost of a repeated
rocedure, makes avoidance of upgrades highly preferable.
For patients without an apparent need for dual-chamber
apability at the time of implant, the optimal approach to
nitial device selection—single- versus dual-chamber—has
ot been investigated. The most common approach in these
atients is to implant a single-chamber device and subse-
uently upgrade to an AV-ICD should the need arise. A
econd approach would be to implant AV-ICDs initially in
ll patients, regardless of clinical need for dual-chamber
apability at the time of implant. Universal implantation of
n AV-ICD is a potentially attractive strategy, because it
ight minimize inappropriate ICD shocks for supraventric-
lar arrhythmias while concomitantly avoiding the need for
ater upgrade from a single-chamber device should brady-
rrhythmias develop. A third approach would be to use
nformation on potential subclinical sinus node or AV node
ysfunction or predisposition to atrial arrhythmias gained
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September 6, 2005:850–7 Cost Advantage of the Dual-Chamber ICDrom electrophysiologic study (EPS) as a means of predict-
ng the future need for dual-chamber capabilities, thus
mploying electrophysiologic-guided assessment as a deter-
inant of device selection. To determine which of these
hree strategies for device selection in patients requiring
CD therapy would be least costly, we constructed a
ecision-analysis model with retrospective data from our
nstitution on device usage.
ETHODS
tudy design. We developed a decision analytic model to
stimate the economic costs of three alternative implanta-
ion strategies in ICD recipients who do not demonstrate
he need for a dual-chamber device at time of implant: 1)
nitial implantation of a single-chamber device in all pa-
ients with later upgrade to an AV-ICD as clinically needed;
) initial implantation of an AV-ICD in all patients; and 3)
argeted initial device selection on the basis of the results of
lectrophysiologic testing. The decision tree in Figure 1
epicts these three choices, their associated costs, and their
ownstream clinical consequences. The choice of a single-
hamber ICD carries the risk that patients will require
ubsequent upgrades to an AV-ICD. By contrast, the
hoice of an AV-ICD removes this risk entirely. With
lectrophysiologic-guided device selection, the upgrade risk
ight be potentially reduced but not entirely eliminated.
Base estimates of outcome probabilities were determined
ith clinical data obtained from retrospective review of data
rom the Yale University School of Medicine electrophysi-
logy practice. Economic inputs for the analysis (including
evice costs, procedure and hospital costs, and professional
ees) were collected from national and local sources. All
onetary outcomes were reported in 2002 U.S. dollars. The
nalysis conforms to the reference case recommendations of
Abbreviations and Acronyms
ACC  American College of Cardiology
AHA  American Heart Association
AV-ICD  atrioventricular (dual-chamber)
implantable cardioverter-defibrillator
AVID  Anti-arrhythmics Versus Implantable
Defibrillators trial
CHF  congestive heart failure
DAVID  Dual-Chamber and VVI Implantable
Defibrillator trial
EPS  electrophysiology/electrophysiologic study
ICD  implantable cardioverter-defibrillator
MADIT  Multicenter Automatic Defibrillator
Implantation Trial
MUSTT  Multicenter UnSustained Tachycardia
Trial
NASPE  North American Society of Pacing and
Electrophysiology
SCD-HeFT  Sudden Cardiac Death in Heart Failure
Trialhe U.S. Panel on Cost-Effectiveness in Health and Med-
a
cine (13). This study was approved by the Yale Human
nvestigational Committee.
etermination of base estimates. We used data from the
ale electrophysiology experience to determine base esti-
ates for the probability of upgrade to AV-ICD after
mplantation of a single-chamber ICD without EPS, the
robability of abnormal EPS, and the probability of upgrade
f electrophysiologic-guided selection is used (i.e., the pre-
ictive accuracy of EPS).
The Yale University Electrophysiology Database and
atient charts were reviewed to identify all patients who
eceived an ICD in the four years after FDA approval of the
V-ICD in June 1997 and to determine whether subse-
uent upgrade was performed. Patients with permanent
trial fibrillation, who had failed attempts at maintenance of
inus rhythm and for whom no further attempts at main-
enance of sinus rhythm were planned, were excluded (n 
3), because these patients could not benefit from an atrial
ead at implantation nor develop indication of benefit from
n atrial lead in follow-up. The remaining 453 patients who
eceived either a single- or dual-chamber ICD between June
997 and July 2001 were included in the analysis.
After the approval of the AV-ICD by the FDA in June
997, Yale electrophysiologists empirically instituted a strat-
gy to implant the AV-ICD in two groups of patients. First,
atients with a clinical need for dual-chamber pacing or
ensing, similar to those later described in the American
ollege of Cardiology/American Heart Association /North
merican Society of Pacing and Electrophysiology (ACC/
HA/NASPE) 2002 Guideline Update for Implantation of
ardiac Pacemakers and Antiarrhythmia Devices (5), re-
eived an AV-ICD. Second, those with abnormal sinoatrial
unction or impaired atrioventricular nodal conduction, or
igure 1. Decision tree. The square node on the left represents a choice
mong the three strategies under examination. The circles represent
hance nodes at each of the associated downstream probabilities for points
f uncertainty. The costs listed are the non-cumulative costs associated
ith that particular point in the decision analytic model. AV-ICD 
trioventricular (dual-chamber) implantable cardioverter-defibrillator; EP
electrophysiologic.
i
p
o
r
s
i
P
f
d
p
a
V
c
t
o
f
t
i
i
d
S
A
fi
w
c
E
w
1
d
a
p
fi
d
t
p
u
A
1
t
t
W
i
f
2
n
c
u
t
a
c
t
E
o
S
c
a
s
d
D
o
o
C
2
s
o
(
s
N
s
p
S
d
p
o
I
I
w
r
m
p
T
I
i
d
n
i
t
p
a
c
F
e
b
A
d
852 Goldberger et al. JACC Vol. 46, No. 5, 2005
Cost Advantage of the Dual-Chamber ICD September 6, 2005:850–7nduced atrial arrhythmias at invasive EPS, performed
re-operatively in all patients according to published meth-
ds (14), received the atrioventricular device. Specific crite-
ia included: corrected sinus node recovery time 540 ms,
inoatrial conduction time 230 ms or His ventricular
nterval 70 ms, or induction of an atrial arrhythmia.
atients without either clinical or electrophysiologic criteria
or AV-ICD implantation received a single-chamber ICD.
Upgrade to AV-ICD was performed if indications for the
ual-chamber device developed at a time after initial im-
lantation; indications included: 1) symptomatic brady-
rrhythmias with symptoms of pacemaker syndrome during
VIR (ventricular rate responsive) pacing (weakness, exer-
ise intolerance or pre-syncope, similar to those specified in
he Mode Selection Trial [MOST] as qualifying for cross-
ver to dual-chamber mode) (15); 2) inappropriate shocks
or supraventricular arrhythmias; or 3) symptomatic conges-
ive heart failure (CHF) with bradycardia or prolonged PR
nterval. At the time of this study, guidelines for AV-ICD
mplantation did not exist and the need for upgrade was
etermined on the basis of presence of these criteria.
ubsequently published series (12,16) and more recent 2002
CC/AHA/NASPE guidelines (5) demonstrate that the
rst two of these criteria for a dual-chamber device remain
idely accepted. The probability of upgrade from a single-
hamber to an AV-ICD device in patients with a normal
PS (who had thus received an initial single-chamber ICD)
as determined in patients receiving an ICD between June
997 and July 2001.
Because all patients who received an ICD at our center
uring these years underwent EPS, and all those with
bnormal findings received AV-ICDs, we determined the
robability of upgrade without EPS via extrapolation. We
rst determined the positive predictive accuracy of the EPS,
efined as the percentage of those with abnormal EPS who
hen underwent later upgrade, in a separate population of 54
atients who received single-chamber devices between Jan-
ary 1996 and June 1997 (before the availability of the
V-ICD). Among these patients, 20 had an abnormal EPS,
2 of whom required upgrade (significantly greater than
hose with normal EPS [11 of 34, 32%, p  0.05]). Thus,
he positive predictive accuracy of EPS was 60% (12 of 20).
e then extrapolated the probability of upgrade for our
nitial population in all patients without clinical indication
or an AV-ICD and without prior EPS, as shown in Figure
. Total upgrades, in the numerator, was based on the
umber of actual upgrades in those receiving a single-
hamber device (normal EPS) plus the number of expected
pgrades in those who had received an AV-ICD by elec-
rophysiologic criteria, on the basis of the positive predictive
ccuracy of the EPS. Total number of patients without
linical indication for EPS, in the denominator, included
hose who received a single-chamber ICD after a normal
PS and those who received an AV-ICD solely on the basis
f an abnormal EPS. dources for economic data. Economic data analyzed was
hosen to reflect resource use and included a combination of
ctual costs to the hospital and professional fees, used as a
urrogate for cost for this aspect of resource use. Economic
ata, listed in Table 1, were derived from three sources.
evice costs to the hospital were national averages formed
n the basis of a survey taken in 2002 from 2,100 members
f the Cardiovascular Roundtable of the Advisory Board
ompany, a national health-practice consortium of over
,000 health care systems. Other hospital costs (overnight
tay and operating room costs) were averages of actual
perational costs for Yale-New Haven Hospital in 2002
e.g., wages, supplies, averaged for a per-person overnight
tay on a cardiac-monitored floor), calculated by the Yale-
ew Haven Hospital internal accounting system. Profes-
ional fees were actual 2002 fees charged by Yale faculty
ractice electrophysiologists and anesthesiologists.
ensitivity analyses. Sensitivity analysis was first con-
ucted on the target population assumption. We first
erformed an analysis for a population of patients without
ther clinical indications for EPS (i.e., meeting criteria for
CD implantation defined in the Anti-arrhythmics Versus
mplantable Defibrillators [AVID] trial) (1). Subsequently,
e analyzed a population of patients undergoing EPS for
isk-stratification to determine the need for ICD (i.e.,
eeting criteria for ICD implantation defined in the
rimary-prevention Multicenter UnSustained Tachycardia
rial [MUSTT] and Multicenter Automatic Defibrillator
mplantation Trial [MADIT I]) (2,3). For this group,
nformation gained from the EPS could be used to guide
evice selection at no additional cost.
We also conducted sensitivity analyses to test the robust-
ess of our conclusions to uncertainty in the underlying
nput data. Specifically, we explored the impact of varying
he following input parameters over a range of values: 1) the
roportion of patients requiring an upgrade to an AV-ICD
fter the initial implantation of single-chamber ICD; 2) the
ost differential between the dual- and single-chamber
igure 2. Extrapolation of upgrade rate for patients not undergoing
lectrophysiologic study (EPS). *Expected upgrade rate, determined on the
asis of positive predictive value of the EPS (see Methods for details).
V-ICD  atrioventricular (dual-chamber) implantable cardioverter-
efibrillator.evices; 3) the timing of upgrade (i.e., cost depreciation);
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September 6, 2005:850–7 Cost Advantage of the Dual-Chamber ICDnd 4) the non-device costs associated with the procedure.
ecause ranges of input data are not available in the
ublished literature, we varied each parameter over plausible
anges.
We also conducted a sensitivity analysis incorporating the
otential for atrial lead dislodgement, requiring lead repo-
itioning, with a base estimate of 4% as described in
ublished reports (16,17).
tatistical analysis. Comparisons of upgrade rates between
atients with normal versus abnormal EPS, and between
atients receiving ICDs for primary versus secondary pro-
hylaxis, were performed with chi-square analysis with JMP
.0 software (SAS Institute, Cary, North Carolina).
ESULTS
tudy population. The population from which the base
stimates were derived was 79% male (mean age 65  13
ears) and 71% had coronary artery disease. Indications for
CD included sustained ventricular tachycardia in 27%,
entricular fibrillation in 18%, and primary sudden death
rophylaxis in 55%. There were no differences in devices
eceived or later upgrades on the basis of any demographic
r clinical variable. Devices implanted and their indications
n the 453 patients who received an ICD between June 1997
nd July 2001 are shown in Figure 3. Among the 271
atients without clinical indication for dual-chamber pacing
t implantation, the probability of an abnormal EPS was
4%.
ase estimates. PROBABILITY OF UPGRADE—NORMAL EPS.
f the 207 patients who had no clinical indications for
ual-chamber pacing and a normal EPS, who therefore
eceived single-chamber ICDs, the probability of upgrade to
V-ICD was 7%. Indications for upgrade in these 15
atients are shown in Figure 3 and included symptomatic
radyarrhythmias in 6 patients (2 with complete heart
lock, 4 with sick sinus syndrome), inappropriate shocks for
aroxysmal atrial fibrillation in four patients, and CHF with
radycardia or prolonged PR interval in 5 patients. There
as no difference in the upgrade rate between those receiv-
ng an ICD for primary sudden death prophylaxis versus for
econdary prophylaxis after a clinical arrhythmia (6.8% vs.
able 1. Economic Inputs
Single-Chamber ICD
(Initial Implantation)
ystem (including device and leads) $22,000
ther hospital costs
Operating room $2,500
Hospital stay $867
EPS procedure
rofessional fees
Electrophysiologist $6,575
Anesthesiologist $1,040
otal $32,982
erivation of costs and fees is described in the text. Costs in 2002 dollars.
AV-ICD  atrioventricular (dual-chamber) implantable cardioverter-defibrillator.6%, respectively, p  0.6).
n
vROBABILITY OF UPGRADE WITHOUT PERFORMANCE OF
PS. Derivation of the probability of upgrade without
erformance of EPS is shown in Figure 2. There were 15
ctual upgrades among the 207 patients implanted with a
ingle-chamber ICD after a normal EPS. Of the 64 patients
ith an abnormal EPS (who had thus received an AV-
CD), on the basis of the 60% positive predictive accuracy of
PS as described previously, the expected number of up-
rades was 38. On the basis of the extrapolation described in
he Methods section, the probability of requiring subse-
uent AV-ICD upgrade without prior EPS was 20%.
ecision analytic model. PATIENTS WITHOUT OTHER IN-
ICATIONS FOR EPS. As shown in Figure 4, in patients
ithout other indications for electrophysiologic testing, the
xpected cost was least with the strategy of universal initial
V-ICD implantation, with an expected per-person cost of
36,232. The strategy of initial single-chamber ICD with
V-ICD upgrade as needed generated an expected per-
erson cost of $39,230. The strategy of EPS before implan-
ation was the most expensive option, with an expected
er-person cost of $41,130. Further analysis with an
igure 3. Initial devices received June 1997 and July 2001 and indications.
ffset represents upgrades received and indications. Values represent
AV-ICD
ial Implantation) Upgrade
Atrial Lead
Repositioning EPS
$25,250 $19,350
$2,500 $2,500 $2,500
$867 $867 $867
$2,700
$6,575 $7,593 $1,667 $3,000
$1,040 $1,040 $1,040
$36,232 $31,350 $6,074 $5,700
 electrophysiologic study.(Initumbers of patients. CHF  congestive heart failure; HV  His
entricular interval; other abbreviations as in Figure 2.
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Cost Advantage of the Dual-Chamber ICD September 6, 2005:850–7nflation-adjusted (at an annual rate of 3%) value for the
pgrade cost, assuming an average upgrade time of 2.5
ears, had no material effect on the cost estimates or
ankings between treatment choices.
ATIENTS UNDERGOING EPS FOR RISK ASSESSMENT. Among
atients who undergo EPS to determine the need for an
CD implant itself (i.e., MADIT 1 and MUSTT popula-
ions), the cost of EPS itself can be excluded from the
alculation. For these patients, use of electrophysiologic-
uided selection was the least costly strategy. In those with
bnormal EPS findings, it is considerably less expensive
$38,000 vs. $53,000) to implant AV-ICDs than single-
hamber ICDs. For those with normal EPS findings,
xpected per-person cost was less with the single-chamber
$34,000 vs. $38,000).
ENSITIVITY ANALYSIS: UPGRADE RATE. Individual clini-
ians may vary in their threshold for initial AV-ICD
mplantation as well as for upgrade, and institutional norms
ight vary. To reflect these practice variations, we explored
pgrade rates ranging from 5% to 35% (baseline assumption
20%). As illustrated in Figure 5, higher upgrade rates will
igure 4. Expected per-person costs of each strategy, initial single-
hamber implantation with upgrade as needed, universal dual-chamber
mplantation (AV-ICD), and use of electrophysiologic study to guide
ecision (EP-guided).
igure 5. Sensitivity analysis, upgrade rate. Input varied from 5% to 35%,
aseline assumption 20%. Arrow denotes threshold of indifference. AV-
CD  atrioventricular (dual-chamber) implantable cardioverter-
efibrillator.
d
croduce higher costs for the strategy of initially implanting
ingle-chamber devices. At an upgrade rate of 10%, the
er-person cost of the initial single-chamber device implan-
ation would be equivalent to the cost of universal AV-ICD
mplantation. Our finding in favor of an AV-ICD is robust
or any upgrade rate assumption greater than this threshold
alue.
ENSITIVITY ANALYSIS: DEVICE COST DIFFERENTIAL.
pgrade rates at some institutions might be lower than
0%. Therefore, we also evaluated how much the cost-
ifferential would need to narrow for the universal AV-ICD
trategy to remain least expensive at an upgrade rate of just
%. As shown in Figure 6, as the cost differential between
he single- and dual-chamber devices narrows, the strategy
f implanting the dual-chamber device in all patients
ncreasingly becomes the least expensive option. A cost
ifferential of $1,568 between the two devices (about
ne-half the current cost differential) would keep the
mplantation of an AV-ICD at initial implant the least
xpensive strategy, even at an upgrade rate as low as 5%.
ENSITIVITY ANALYSIS: TIMING OF UPGRADE. Because the
iming of upgrade will impact the long-term cumulative
osts of ICD therapy, we also performed a sensitivity
nalysis varying the timing of upgrade assuming a straight-
ine depreciation of device value over time, with other
ariables held constant. Universal AV-ICD implantation
emains the least expensive strategy at this upgrade rate,
ssuming that a mean of at least 52% battery life remains at
he time of upgrade.
ENSITIVITY ANALYSIS: NON-DEVICE COSTS. We examined
he impact of varying other costs, including professional fees
nd hospital costs, on the baseline $3,000 cost advantage of
he AV-ICD strategy. As shown in Figure 7, varying
on-device cost estimates from 50% to 200% of their
riginal values did not alter the cost advantage of universal
V-ICD implantation.
igure 6. Sensitivity analysis, cost-differential, assuming 5% upgrade rate.
nput varied from $500 to $3,000, current cost-differential $32,940. Arrow
enotes threshold of indifference. AV-ICD  atrioventricular (dual-
hamber) implantable cardioverter-defibrillator.
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September 6, 2005:850–7 Cost Advantage of the Dual-Chamber ICDENSITIVITY ANALYSIS: ATRIAL LEAD REPOSITIONING. As-
uming an atrial lead repositioning rate of 4% (cost listed in
able 1), initial AV-ICD implantation remains the least
xpensive strategy. Sensitivity analysis reveals that an atrial
ead repositioning rate of 61% would be needed to reverse
he cost advantage of the AV-ICD.
ISCUSSION
he AV-ICD is a more expensive device than the single-
hamber ICD; however, this decision analysis demonstrates
hat the strategy of universal AV-ICD implantation, re-
ardless of clinical need or EPS results, is a dominant
trategy that first, offers the benefits of dual-chamber
apabilities for all patients and obviates the need for future
pgrade, and second, does so at a lower cost to the health
are system than would a strategy of initial implantation of
he less-expensive single-chamber device. The cost advan-
age of the AV-ICD strategy was robust in the face of
lausible uncertainty in upgrade rates, timing of upgrade,
nd other costs. Even at an upgrade as low as 5%, the
niversal AV-ICD strategy would remain the least expen-
ive option if the cost difference between the single-chamber
nd AV devices was reduced to just $1,568, roughly one-
alf of the current cost-difference. Ultimately, a reduction of
he baseline cost of the AV-ICD by device manufacturers by
his marginal amount could allow all patients to receive the
V-ICD at implant and obviate the need for future
pgrade.
In our study, we describe the advantages of implanting
ual-chamber hardware to preempt a later need for upgrade
o dual-chamber pacing capabilities should the need for
radycardia pacing or supraventricular arrhythmia discrim-
nation develop. Our results do not imply that devices be
rogrammed for dual-chamber pacing. The recent Dual
igure 7. Sensitivity analysis, non-device costs. Input for each cost varied
rom 50% to 200% of baseline values. The x-axis represents the cost-
dvantage of the atrioventricular (dual-chamber) implantable cardioverter-
efibrillator (AV-ICD) strategy over the single-chamber strategy. The
ertical line represents the $3,000 cost advantage of the AV-ICD strategy
ssuming baseline values. At no variation of input values does the AV-ICD
trategy become more expensive (cross zero).hamber and VVI Implantable Defibrillator (DAVID) trial D18) challenged the prior conventional wisdom that dual-
hamber pacing is beneficial in patients with heart failure,
emonstrating that right ventricular pacing can exacerbate
HF, presumably by creating asynchronous contraction
ith resultant impaired cardiac output (19). In the MOST
tudy, for patients with pacemakers programmed DDD,
eart failure hospital stays increased as percentage of ven-
ricular pacing increased (20). Similarly, in the MADIT II
tudy, patients receiving AV-ICDs were more likely to be
ospitalized for heart failure than single-chamber recipients
21), although, because MADIT II was enrolling before
ublication of the DAVID trial, it is unlikely that efforts
ere made to avoid right ventricular pacing. Since the
AVID study, randomized trials have evaluated pacing
odalities that allow atrial-based pacing while minimizing
ight ventricular pacing. For example, programming of the
DI/R mode can decrease ventricular pacing while provid-
ng “functional AAI/R pacing” for most patients (22).
ecent innovations in device technology give further pro-
ramming flexibility to decrease right ventricular pacing
ith a dual-chamber system. For example, one algorithm
mploying an atrioventricular search function has shown, in
atients with a variety of baseline PR intervals, the ability to
ace the atrium while pacing the right ventricle 3% of the
ime (23,24). Thus, implantation of the dual-chamber
evice, through the option of atrial pacing, can decrease the
ikelihood of ventricular pacing exacerbations of CHF.
It is a limitation of our study that some upgrades were
erformed for CHF (with bradycardia or prolonged PR
nterval). This was a reasonable approach at the time of the
tudy (1997 to 2001), but is now obsolete after the publi-
ation of the DAVID trial (18) and the availability of
ardiac resynchronization therapy, which improves mortal-
ty (25) as well as symptoms (26) in patients with heart
ailure. To what extent the availability of this device, now
6% to 30% of ICDs implanted (industry data, Medtronic
nc., and Guidant Corp.), might impact the implications of
ur findings is unknown. Patients implanted with an AV-
CD who develop heart failure now would receive upgrade
o a biventricular device, potentially offsetting an unknown
raction of the cost advantage of the strategy of universal
V-ICD implantation. Exclusion from our analysis of the
atients who underwent upgrade for CHF, however, still
eaves the upgrade rate higher than that demonstrated to
how economic benefit from universal AV-ICD implanta-
ion. Whether there is a patient population for whom
rophylactic implantation of a left ventricular lead would
imilarly result in lower total health care costs requires
urther clinical and economic analyses.
Since the end of our data collection, indications for ICDs
ave expanded on the basis of the results of MADIT II (4),
hich showed decreased mortality with the ICD in patients
ith a history of myocardial infarction and ejection fraction
30%, without EPS stratification, and the Sudden Cardiac
eath in Heart Failure Trial (SCD-HeFT) (27), showing
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Cost Advantage of the Dual-Chamber ICD September 6, 2005:850–7ortality benefit of the ICD in those with New York Heart
ssociation functional class II or III CHF and ejection
raction 35%. Whether later development of need for
ual-chamber capability would be comparable in the
ADIT II or SCD-HeFT populations to that which we
bserved is not known. In the current study, there were no
ifferences in upgrade rates between those receiving ICDs
or primary prophylaxis, as defined by MADIT and
USTT, versus secondary prophylaxis. It is doubtful that
he upgrade rates would differ considerably for MADIT
I-type patients, because the differences in inclusion criteria
etween MADIT II and the previous primary prophylaxis
rials—the absence of inducible ventricular tachycardia and
ower ejection fraction—would be unlikely to lower the
robability of development of atrial or bradyarrhythmias.
hether upgrade rates would be similar in the SCD-HeFT
opulation, one-half of whom had non-ischemic cardiomy-
pathies, requires further study.
In the SCD-HeFT study, mortality benefit was seen with
single-lead device, and on the basis of this, the Center for
edicare and Medicaid Services has announced reimburse-
ent of only these devices for patients receiving ICDs for
rimary prophylaxis unless medical need is documented
28). Detailed data from SCD-HeFT, however, such as
ccurrence of inappropriate shocks or need for atrial-based
acing, as would suggest benefit from AV-ICD, has not
een reported. The current analysis suggests that further
tudy in that population is needed regarding the medical
nd economic soundness of this policy.
omparison with other studies. Previous studies have
ited indications for AV-ICD implantation along with
pgrade rates but have not evaluated costs associated with
heir use (12,17). The overall cost-effectiveness of the ICD
s comparable to that of other life-saving therapies (29), but
he costs of single-versus dual-chamber implantation were
ot evaluated. Other previous studies have reported predic-
ive accuracies of EPS lower than those reported here. In
hese studies, the EPS performed poorly in documenting
yncope caused by transient bradycardia (30–32). In con-
rast, we found that the EPS performed well in predicting
he need for upgrade. Because a prolonged His ventricular
nterval might be an indicator of poor left ventricular
unction and sinus node disease might be associated with
trial arrhythmias, the ability of EPS to predict develop-
ent of any cause for upgrade might be higher than the
redictive accuracy for specific bradyarrhythmias.
Improved discrimination between ventricular and su-
raventricular arrhythmias, with presumed reduction in
nappropriate shocks, was taken as indication for AV-ICD
mplantation, as it has been in other series (12,16), and as is
eemed appropriate by recent ACC/AHA/NASPE guide-
ines (5). Large comparative studies of single-versus dual-
hamber algorithms are lacking, however, and are difficult to
erform given the number of devices and rapidly evolving pechnologies. Retrospective comparisons suggest that dual-
hamber algorithms discriminate supraventricular from ven-
ricular tachycardias with higher sensitivity and specificity
han do single-chamber algorithms (9,10). One prospective
andomized study showed a decrease in inappropriate
hocks with a dual-chamber algorithm in patients with a
istory of ventricular tachycardias 200 beats/min (33),
hereas another, in an unselected population, did not (34).
owever, the percentage of patients receiving inappropriate
hocks in both groups in the latter study was higher than in
ther series of dual-chamber devices (9,10). Improved
ual-chamber tachycardia discrimination is a subject of
ctive ongoing investigation (35,36).
odeling limitations. Like all clinical policy models, our
tudy is limited by the quality of its input data. We are
indful that our clinical data were obtained via a retrospec-
ive analysis in a single center. These data might not be
pplicable to decisions in other institutions and might
ven be inaccurate for setting policy. To date, however,
here are no randomized trials comparing single-chamber
evices to AV-ICDs or evaluating upgrade rates, which
ould provide more generalized data for purposes of
ecision support. Given the paucity of hard evidence in
his area, it seems appropriate to examine threshold
alues and boundaries that might trigger a material
hange in decision making.
We are also mindful that we have assembled our eco-
omic input data from a variety of sources. Synthesis of cost
ata from diverse sources introduces the risk of mismatched
stimates, reflecting different patient populations and sig-
ificant differences in the costs of care from one geographic
rea to another. Here again, we have attempted to explore
hese possibilities via sensitivity analysis on each cost com-
onent. In general, we have found that our results are robust
ver plausible variation in the underlying cost data. Use of
osts primarily from one center limits the direct generaliz-
bility to other centers; however, whereas reimbursements
ould not be center-specific, these might not reflect true
esource use as accurately as do costs.
Some patients from the pre-AV-ICD group who under-
ent later upgrade might have had clinical indications for
V-ICD implantation, thus overestimating the positive
redictive value of the EPS, and thus, the extrapolated
pgrade rate. Sensitivity analyses, however, revealed the
ndings robust for much lower upgrade rates than our
aseline estimate.
onclusions. Although perhaps counterintuitive, the ini-
ial implantation of the more expensive dual-chamber de-
ice, which provides the benefits of dual-chamber capability
hile obviating any potential need for future upgrade, is the
east costly overall strategy in most patient populations
eceiving ICDs. As indications for ICDs and the available
echnologies continue to expand, whether initial implanta-
ion of AV-ICDs will be the least expensive option in other
opulations requires further investigation.
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